pentetreotide
PeptideexperimentalImaging agent
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 25, 1999 (NCT00001849)
Timeline
1990s
- Jan 1, 1999
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- SomatostatinSupplementation
SST supplementation
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Imaging
- 111-indium
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2108757 ↗
Also known as
- dtpa-sms
- l-cysteinamide, n-(2-((2-(bis(carboxymethyl)amino)ethyl)(carboxymethyl)amino)ethyl)-n-(carboxymethyl)glycyl-d-phenylalanyl-l-cysteinyl-l-phenylalanyl-d-tryptophyl-l-lysyl-l-threonyl-n-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (3-8)-disulfide, (r-,(r*,r*))-
- pentetreotide
- pentetreotide
- pentetreotide
- pentetreotide
- pentetreotide
- sdz-215811
- sdz-215811s
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00001849 | Phase 1/Phase 2 (Phase 2) | Feb 25, 1999 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH) |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Government | 1 | 0 | 1 | 1999 |
| National Institutes of Health (NIH) | Government | 1 | 1 | 1 | 1999 |
2 organizations
Page 1 / 1